On August 28, PHARMARON fell 3.38% in regular trading, trading at HK$29.18/share, with turnover of HK$57.24 million.

The decline is driven by continued market concerns over potential share dilution following the company's announcement to issue RMB 2.18 billion zero-coupon USD-settled convertible bonds due August 2027. The board formally approved the proposal on August 27. The initial conversion price is set at HK$36.08 per H share, representing a 16.76% premium to the August 26 closing price. If fully converted, approximately 70.48 million new H shares would be issued, accounting for 3.70% of the enlarged total share capital. The bonds were subscribed by no fewer than six independent investors, with settlement tentatively scheduled for September 2.

Additionally, the broader CXO sector continued to trade under pressure, with GENSCRIPT BIO down 4.34% and WUXI XDC down 3.77%, amplifying the downward momentum through sector-wide selling.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)